健保碼及健保價

See related Volibris film-coated tab[肺博舒膜衣錠] information

製造商

GlaxoSmithKline

代理/經銷商

GlaxoSmithKline

成份

Ambrisentan

適應症

Treatment of pulmonary arterial HTN (PAH).

用量

Adult & adolescents > 18 years Initially, 5 mg once daily. May increase to 10 mg once daily. Co-administration with cyclosporine A 5 mg once daily.

用法

May be taken with or without food (Swallow whole, do not split/ chew/ crush.).

美國食品藥物管理局之懷孕等級

Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

禁忌

Pregnancy.

注意事項

Hepatic aminotransferases should be eva luated prior to initiation of treatment. Treatment should not be initiated in patients with baseline values of ALT &/or AST > 3x ULN. Not recommended for patients with clinically significant anemia. Monitor Hb &/or hematocrit levels during treatment. Patients with pre-existing fluid overload should be managed as clinically appropriate prior to starting therapy. If PAH patients develop acute pulmonary edema during treatment, the possibility of pulmonary veno-occlusive disease should be considered. Lactation.

不良反應

Anemia (decreased Hb, decreased hematocrit), headache, palpitation, flushing, nasal congestion, sinusitis, nasopharyngitis, abdominal pain, constipation, fluid retention, peripheral edema.
View ADR Monitoring Website[參閱藥物不良反應監測表格]

交互作用

Increased ambrisentan concentration when co-administer with cyclosporine A. Initial increase in ambrisentan concentration when co-administer with rifampicin.
View more drug interactions with Volibris[肺博舒]

本商品之市售規格

劑型

包裝

圖片

Volibris 膜衣錠

Volibris 5 mg

Volibris 10 mg